Future studies are needed at both preclinical and clinical level to assess whether RFA in combination with CD73 inhibitors may effectively synergize therapy response by enhancing RFA anti-tumor immunity with the decreased immunosuppression associated with ADO pathway inhibition. The gene discussed is ADO; the disease is neoplasm.